Could immune cell therapy tame chronic GVHD?
NCT ID NCT01937468
First seen Nov 01, 2025 · Last updated Jun 16, 2026 · Updated 31 times
Summary
This early-phase trial tests the safety of combining donor anti-inflammatory Treg cells with low-dose interleukin-2 (IL-2) in 25 people who have chronic graft-versus-host disease (cGVHD) that did not respond to steroids. cGVHD is a complication after a stem cell transplant where the donor's immune cells attack the recipient's body. The goal is to find a safe dose that may help control the disease without causing severe side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC GRAFT VERSUS HOST DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Brigham and Women's Hospital
Boston, Massachusetts, 02215, United States
-
Dana-Farber Cancer Insitute
Boston, Massachusetts, 02215, United States
Conditions
Explore the condition pages connected to this study.